| Literature DB >> 26715493 |
Laura A L Dillon1,2, Rahul Suresh3, Kwame Okrah4, Hector Corrada Bravo5,6, David M Mosser7, Najib M El-Sayed8,9,10.
Abstract
BACKGROUND: Parasites of the genus Leishmania are the causative agents of leishmaniasis, a group of diseases that range in manifestations from skin lesions to fatal visceral disease. The life cycle of Leishmania parasites is split between its insect vector and its mammalian host, where it resides primarily inside of macrophages. Once intracellular, Leishmania parasites must evade or deactivate the host's innate and adaptive immune responses in order to survive and replicate.Entities:
Mesh:
Year: 2015 PMID: 26715493 PMCID: PMC4696162 DOI: 10.1186/s12864-015-2237-2
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Characterization of L. major intracellular growth and proportion of RNA from the parasite. Mouse macrophages infected with L. major were collected at 4, 24, 48, and 72 hpi and subjected to transcriptional profiling by RNA-seq. An average of 87 % of macrophages were infected across all samples. Bar plots are used to illustrate a the average number of parasites observed per 100 host cells and b the average percentage of trimmed RNA-seq reads that map to the L. major genome. Standard errors bars are shown. No statistically significant changes were observed between timepoints
Fig. 2Global gene expression profiles of L. major parasites and their murine macrophage host cells. RNA-seq was carried out on mouse macrophages infected with L. major at 4, 24, 48, and 72 hpi as well as on the metacyclic promastigotes used for the infection. Principal component analysis (PCA) plots and heatmaps of hierarchical clustering analyses using Euclidean distance are shown for the L. major (a, c) and mouse (b, d) transcriptomes over the course of the experiment. The analyses were performed using all annotated protein-coding genes following filtering for low counts and quantile normalization after accounting for batch effects in the statistical model (8479 genes for L. major and 12552 genes for mouse). In the PCA plots, the first two principal components are shown on the X and Y axes, respectively, with the proportion of total variance attributable to that PC indicated. Each experimental sample is represented as a single point with color indicating sample type/timepoint and shape indicating experimental batch. Colors along the tops of the heatmaps indicate the sample type/timepoint and colors along the left sides of the heatmaps indicate the experimental batch. Samples are named according to sample type (“metac” for L. major metacyclic promastigotes, “amast” for L. major amastigotes, “uninf” for uninfected mouse macrophage, or “inf” for L. major-infected mouse macrophage), timepoint (4, 24, 48, or 72 hpi) and experimental batch (a, b, or c) (see Additional file 1)
Fig. 3Differentially expressed genes in L. major parasites and their murine macrophage host cells. RNA-seq was carried out on mouse macrophages infected with L. major at 4, 24, 48, and 72 hpi as well as on the metacyclic promastigotes used for the infection. Pairwise comparisons were done to determine differentially expressed (DE) genes from uninfected vs. infected mouse samples at each timepoint (a, top) and between timepoints (a, middle), and for L. major parasite samples between timepoints (a, bottom). Box length depicts the number of DE genes either downregulated (left) or upregulated (right) at an adjusted P value of < 0.05 with the total number of down- and upregulated genes shown. Color hue indicates sample type/timepoint as defined in Fig. 2 and color shade indicates the proportion of genes with > 4-fold differential expression (dark), between 2- and 4-fold differential expression (medium), or 2-fold differential expression (light). The DE gene lists for uninfected vs. infected mouse cells at each timepoint were compared and the overlap shown as a Venn diagram in (b). The complete lists of DE genes are provided in Additional file 3 for mouse and Additional file 6 for L. major
KEGG pathways enriched in murine macrophages at 4 hpi. KEGG pathway analysis using ConsensusPathDB [58] identified signaling and metabolic pathways that were over-represented in L. major-infected mouse macrophages at 4 hpi (P value < 0.01) relative to uninfected controls. Genes that were differentially expressed (DE) by more than 2-fold were used as input with up- and downregulated genes considered separately. For each enriched KEGG pathway, the number of DE genes assigned to that pathway, the total number of genes in the pathway, and the P value for the enrichment are reported. The differentially expressed genes corresponding to each enriched KEGG pathway are reported in Additional file 4
| KEGG pathway, upregulated | Number DE Genes | Pathway Size |
|
| Cytokine-cytokine receptor interaction | 43 | 266 | 3.49e-12 |
| TNF signaling pathway | 24 | 111 | 3.05e-09 |
| Transcriptional misregulation in cancer | 24 | 180 | 5.72e-09 |
| HIF-1 signaling pathway | 20 | 113 | 4.57e-07 |
| Hematopoietic cell lineage | 16 | 87 | 5.84e-07 |
| NF-kappa B signaling pathway | 19 | 102 | 1.55e-06 |
| Jak-STAT signaling pathway | 22 | 155 | 2.24e-06 |
| Legionellosis | 13 | 59 | 1.05e-05 |
| PI3K-Akt signaling pathway | 37 | 353 | 6.29e-05 |
| MAPK signaling pathway | 28 | 257 | 2.57e-04 |
| Salmonella infection | 12 | 79 | 9.24e-04 |
| Malaria | 9 | 49 | 1.00e-03 |
| NOD-like receptor signaling pathway | 10 | 59 | 1.03e-03 |
| Rheumatoid arthritis | 12 | 84 | 1.60e-03 |
| Glycolysis/Gluconeogenesis | 9 | 65 | 2.19e-03 |
| Mineral absorption | 8 | 46 | 2.72e-03 |
| ECM-receptor interaction | 11 | 87 | 6.42e-03 |
| Tuberculosis | 18 | 177 | 6.45e-03 |
| Gap junction | 11 | 88 | 7.00e-03 |
| Axon guidance | 14 | 129 | 8.88e-03 |
| Arginine and proline metabolism | 8 | 56 | 9.30e-03 |
| Prion diseases | 6 | 35 | 9.77e-03 |
| KEGG pathway, downregulated | Number DE Genes | Pathway Size |
|
| Osteoclast differentiation | 21 | 126 | 2.99e-06 |
| Terpenoid backbone biosynthesis | 7 | 21 | 7.30e-05 |
| Staphylococcus aureus infection | 11 | 52 | 7.61e-05 |
| Steroid biosynthesis | 6 | 17 | 1.71e-04 |
| NOD-like receptor signaling pathway | 10 | 59 | 2.51e-04 |
| Peroxisome | 12 | 81 | 1.18e-03 |
| PPAR signaling pathway | 12 | 81 | 1.18e-03 |
| Chagas disease (American trypanosomiasis) | 14 | 104 | 1.24e-03 |
| Biosynthesis of unsaturated fatty acids | 6 | 25 | 1.69e-03 |
| Leishmaniasis | 10 | 66 | 2.50e-03 |
| ABC transporters | 8 | 46 | 2.75e-03 |
| Axon guidance | 15 | 129 | 3.69e-03 |
| Leukocyte transendothelial migration | 14 | 121 | 5.16e-03 |
| Fc gamma R-mediated phagocytosis | 11 | 89 | 7.70e-03 |
| Pancreatic cancer | 9 | 67 | 9.02e-03 |
Gene ontology (GO) categories enriched across L. major stages/timepoints. GOseq [101] was used to identify enriched GO categories for the transition between metacyclic promastigotes and 4-h amastigotes and between 4-h amastigotes and 24-h amastigotes at a P value cutoff of < 0.05. For each transition, up- and downregulated genes were considered separately. The category for each enriched GO term is indicated (BP = biological process, MF = molecular function, CC = cellular component). The differentially expressed genes corresponding to each enriched GO category are reported in Additional file 7
| GO ID | GO term |
|
|---|---|---|
| Metacyclics to 4-h amastigotes, upregulated | ||
| GO:0006950 | response to stress (BP) | 5.50E-13 |
| GO:0006486 | protein glycosylation (BP) | 9.95E-09 |
| GO:0006457 | protein folding (BP) | 5.70E-06 |
| GO:0051920 | peroxiredoxin activity (MF) | 2.72E-05 |
| GO:0051082 | unfolded protein binding (MF) | 9.44E-05 |
| GO:0016209 | antioxidant activity (MF) | 1.04E-04 |
| GO:0004386 | helicase activity (MF) | 2.06E-04 |
| Metacyclics to 4-h amastigotes, downregulated | ||
| GO:0004713 | protein tyrosine kinase activity (MF) | 6.68E-12 |
| GO:0004674 | protein serine/threonine kinase activity (MF) | 2.15E-11 |
| GO:0004672 | protein kinase activity (MF) | 3.40E-10 |
| GO:0006468 | protein phosphorylation (BP) | 3.43E-10 |
| GO:0005516 | calmodulin binding (MF) | 2.76E-08 |
| GO:0009434 | microtubule-based agellum (CC) | 1.93E-07 |
| GO:0005840 | ribosome (CC) | 8.85E-07 |
| GO:0006412 | translation (BP) | 1.42E-06 |
| GO:0003735 | structural constituent of ribosome (MF) | 1.81E-06 |
| GO:0006633 | fatty acid biosynthetic process (BP) | 2.72E-05 |
| GO:0009190 | cyclic nucleotide biosynthetic process (BP) | 8.29E-05 |
| GO:0016849 | phosphorus-oxygen lyase activity (MF) | 8.29E-05 |
| GO:0007165 | signal transduction (BP) | 2.66E-04 |
| 4-h to 24-h amastigotes, upregulated | ||
| GO:0005874 | microtubule (CC) | 3.25E-09 |
| GO:0043234 | protein complex (CC) | 5.80E-09 |
| GO:0051258 | protein polymerization (BP) | 5.80E-09 |
| GO:0005198 | structural molecule activity (MF) | 3.32E-08 |
| GO:0006184 | GTP catabolic process (BP) | 3.91E-07 |
| GO:0007018 | microtubule-based movement (BP) | 9.88E-06 |
| GO:0003924 | GTPase activity (MF) | 1.81E-05 |
| 4-h to 24-h amastigotes, downregulated | ||
| GO:0055114 | oxidation-reduction process (BP) | 8.81E-08 |
| GO:0006096 | glycolytic process (BP) | 1.24E-07 |
| GO:0020015 | glycosome (CC) | 4.22E-07 |
| GO:0004743 | pyruvate kinase activity (MF) | 1.50E-05 |
| GO:0050661 | NADP binding (MF) | 2.36E-05 |
| GO:0004365 | GAPDH (NAD+) (phosphorylating) activity (MF) | 5.91E-05 |
| GO:0006006 | glucose metabolic process (BP) | 1.45E-04 |